Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator
Executive Summary
The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.
You may also be interested in...
Medicare Expands Coverage For Spinal Cord Stimulation To Treat Diabetic Peripheral Neuropathy
Medicare’s recent expansion of coverage for spinal cord stimulation therapy to treat diabetic peripheral neuropathy could mean relief for some 11 million Americans. Executives from Redwood City, CA device maker Nevro talked to Medtech Insight about the expansion and what it means for patients who use their technology.
Exec Chat: Abbott’s Burton Talks About Abbott’s Plans To Address Chronic Pain With SCS
Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s new labeling for Abbott’s spinal cord stimulation devices that includes non-surgical back pain.
Nevro Names Kevin Thornal As Its New CEO; Investors Remain Disappointed In Results
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.